A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Completed · Phase 2 · NCT05291234
Conditions: Alzheimer's Disease (AD)
At a glance
- Research payments reported, 2025
- $3.0M
- U.S. investigators named
- 31
- Sites paid
- 40
- Planned or actual enrollment
- 106
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-916 (drug), Placebo (drug)
- Dates
- Started 2022-08-15; completion 2025-11-19
- Results posted
- Not yet
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of ea…
From ClinicalTrials.gov, last updated 2025-12-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.0M in research payments for this study in 2025 (268 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric M. Chavez, MD Psychiatry · San Diego, CA
- John G. Duffy, MD Psychiatry · Santa Ana, CA
- Elly R. Lee, MD Psychiatry · Irvine, CA
- Raymond S. Turner, MD,PHD Neurology · Washington, DC
- Sheila M. Baez-torres, M.D. Neurology · Winter Park, FL
- Adam D. Falchook, MD Neurology · Stuart, FL
- Christopher M. Galloway, MD Family Medicine · Melbourne, FL
- Rekha Gandhi, MD Neurology · Winter Park, FL
- Mark Goldstein, MD Neurology · Atlantis, FL
- Yaneicy Gonzalez Rojas, MD Internal Medicine · Coral Gables, FL
- Uzma Khan, MD Internal Medicine · The Villages, FL
- David A. Kirk Family Medicine · Merritt Island, FL
- Rosemary D. Laird, MD Geriatric Medicine · Viera, FL
- Ramon Leon, MD Family Medicine · Miami, FL
- David J. Mcdonald, MD Neurology · Ormond Beach, FL
- Anette Nieves, MD Neurology · Ocala, FL
- Michael M. Pfeffer, MD Neurology · Miami, FL
- Edgardo J. Riverarivera, MD Emergency Medicine · Leesburg, FL
- Lilia Rodriguez Ables, MD General Practice · Miami, FL
- Reinhard E. Rott, MD-MBA General Practice · Temple Terrace, FL
- Julie B. Schwartzbard, MD Neurology · Aventura, FL
- Paul K. Winner, D.O. Child Neurology · West Palm Beach, FL
- Jonathan L. Liss, M.D. Neurology · Columbus, GA
- Jeffrey A. Norton, M.D. Pain Medicine · Lawrence, MA
- Aaron L. Ellenbogen, D.O. Neurology · Farmington Hills, MI
- Mohammad R. Bolouri, MD Neurology · Matthews, NC
- Ashok A. Patel, MD Cardiology · Bridgewater, NJ
- Sanjiv K. Sharma, M.D. Internal Medicine · Toms River, NJ
- Cherian Verghese, M.D Psychiatry · Norristown, PA
- Parke J. Hedges OB-GYN (Obstetrics & Gynecology) · San Antonio, TX
- David Watson Emergency Medicine · Fort Hood, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- K2 Medical Research LLC $417,231
- Alzheimer S Research and Treatment $353,696
- Irvine Center for Clinical Research $335,546
- Clincloud LLC $324,830
- Columbus Memory Center LLC $270,403
- K2 Medical Research Maitland LLC $190,370
- Conquest Research LLC $144,628
- Optimus U Corp $133,855
- Finlay Medical Research Corp $109,069
- Neurology Associates of Ormond Beac $107,447
- Charter Research LLC $88,003
- Visionary Investigators Network $83,768
- Ecir Miami Holdings LLC $82,277
- Advanced Memory Research Institute $73,422
- Artemis Headlands LLC $54,489
- Tandem Intermediate LLC $52,978
- Merritt Island Medical Research $46,145
- Raa Apex Acquisition LLC $30,663
- Jem Headlands LLC $20,533
- Clinical Trials of Texas LLC $15,903
- Bio Behavioral Health $13,500
- Allied Biomedical Research Institute $5,300
- Renstar LLC $5,258
- Quest Research Institute LLC $3,000
- Amc Research LLC $2,600
- Keystone Clinical Studies LLC $1,325
- Alzheimer's Research and Treatment $1,200
- Headlands Horizons LLC $700
- Finlay Medical Research Corporation $600
- K2 Medical Research $600
- Irvine Clinical Research $600
- Imic Inc $600
- Jem Research LLC Mark $600
- Advanced Memory Research Institute of New Jersey $600
- Interspond LLC $600
- Quest Research Institute $350
- Renstar Medical Research $300
- Premiere Research Institute $300
- Re Cognition Health Corporation $300
- Flourish Research San Antonio $300
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.